Increased Risks of Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis Among 24,577 First-degree Relatives of 11,039 Patients with Myeloproliferative Neoplasms in Sweden

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 May 3

PMID 18451307

Citations 90

Authors

Ola Landgren

Lynn R Goldin

Sigurdur Y Kristinsson

Elin A Helgadottir

Jan Samuelsson

Magnus Bjorkholm

Affiliations

Soon will be listed here.

Abstract

Previous small studies have reported familial clustering of myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). We identified 6217 PV, 2838 ET, 1172 MF, and 812 MPN unclassifiable (NOS) patients diagnosed in Sweden, 43 550 controls, and first-degree relatives of cases (n = 24 577) and controls (n = 99 542). Using a marginal survival model, we calculated relative risks (RRs) and 95% confidence intervals as measures of familial aggregation. Relatives of MPN patients had significantly increased risks of PV (RR = 5.7; 3.5-9.1), ET (RR = 7.4; 3.7-14.8), and MPN NOS (RR = 7.5; 2.7-20.8). Analyses stratified by type of first-degree relative revealed consistently higher risks for siblings, compatible with a model of recessive genetic inheritance, which can be confirmed only by identifying the susceptibility gene(s). Mean age at MPN diagnosis was not different (P = .20) for affected relatives of cases (57.5 years) versus controls (60.6 years), and risk of MPN by age was not different for parents versus offspring of MPN cases (P = .10), providing no support for anticipation. Relatives of MPN patients had a borderline increased risk of chronic myeloid leukemia (CML; RR = 1.9; 0.9-3.8; P = .09). Our findings of 5- to 7-fold elevated risk of MPNs among first-degree relatives of MPN patients support the hypothesis that common, strong, shared susceptibility genes predispose to PV, ET, MF, and possibly CML.

Citing Articles

Evaluation of the L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms.

Borsani O, Jager R, Pietra D, Flieder I, Riccaboni G, Kralovics R Haematologica. 2024; 109(8):2738-2740.

PMID: 38654656 PMC: 11290499. DOI: 10.3324/haematol.2024.285539.

Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms.

Lekovic D, Ivanovic J, Terzic T, Perunicic Jovanovic M, Dencic Fekete M, Jovanovic J J Clin Med. 2024; 13(6).

PMID: 38542040 PMC: 10971563. DOI: 10.3390/jcm13061816.

COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.

Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani M Cell Commun Signal. 2024; 22(1):126.

PMID: 38360719 PMC: 10868124. DOI: 10.1186/s12964-023-01316-9.

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.

Pettersson H, Adamsson J, Johansson P, Nilsson S, Palmqvist L, Andreasson B Front Oncol. 2023; 13:1190305.

PMID: 37637067 PMC: 10451068. DOI: 10.3389/fonc.2023.1190305.

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.

Stuckey R, Bilbao-Sieyro C, Segura-Diaz A, Gomez-Casares M Int J Mol Sci. 2023; 24(16).

PMID: 37628880 PMC: 10454334. DOI: 10.3390/ijms241612700.

References

Kutti J, Wadenvik H . Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma. 1996; 22 Suppl 1:41-5. DOI: 10.3109/10428199609074359. View

Tefferi A, Fonseca R, Pereira D, HOAGLAND H . A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001; 76(1):22-8. DOI: 10.4065/76.1.22. View

Tefferi A, Elliott M . Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007; 33(4):313-20. DOI: 10.1055/s-2007-976165. View

Andreasson B, Lofvenberg E, Westin J . Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. Eur J Haematol. 2005; 74(6):489-95. DOI: 10.1111/j.1600-0609.2005.00424.x. View

BERLIN N . Diagnosis and classification of the polycythemias. Semin Hematol. 1975; 12(4):339-51. View

Kralovics R, Stockton D, Prchal J . Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003; 102(10):3793-6. DOI: 10.1182/blood-2003-03-0885. View

Rumi E, Passamonti F, Della Porta M, Elena C, Arcaini L, Vanelli L . Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007; 25(35):5630-5. DOI: 10.1200/JCO.2007.12.6896. View

Tefferi A, Vardiman J . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2007; 22(1):14-22. DOI: 10.1038/sj.leu.2404955. View

Kralovics R, Teo S, Li S, Theocharides A, Buser A, Tichelli A . Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006; 108(4):1377-80. DOI: 10.1182/blood-2005-11-009605. View

10.

Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C . Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006; 108(1):346-52. DOI: 10.1182/blood-2005-12-4852. View

11.

Rumi E, Passamonti F, Pietra D, Della Porta M, Arcaini L, Boggi S . JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006; 107(9):2206-11. DOI: 10.1002/cncr.22240. View

12.

Pardanani A, Fridley B, Lasho T, Gilliland D, Tefferi A . Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2007; 111(5):2785-9. DOI: 10.1182/blood-2007-06-095703. View

13.

Skoda R, Prchal J . Lessons from familial myeloproliferative disorders. Semin Hematol. 2005; 42(4):266-73. DOI: 10.1053/j.seminhematol.2005.08.002. View

14.

Cario H, Goerttler P, Steimle C, Levine R, Pahl H . The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol. 2005; 130(5):800-1. DOI: 10.1111/j.1365-2141.2005.05683.x. View

15.

Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A . Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood. 2006; 107(11):4572-3. DOI: 10.1182/blood-2005-12-4988. View

16.

Tefferi A, Gilliland D . Oncogenes in myeloproliferative disorders. Cell Cycle. 2007; 6(5):550-66. DOI: 10.4161/cc.6.5.3919. View

17.

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M . Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004; 117(10):755-61. DOI: 10.1016/j.amjmed.2004.06.032. View

18.

Liang K . Estimating effects of probands' characteristics on familial risk: I. Adjustment for censoring and correlated ages at onset. Genet Epidemiol. 1991; 8(5):329-38. DOI: 10.1002/gepi.1370080505. View

19.

Pfeiffer R, Goldin L, Chatterjee N, Daugherty S, Hemminki K, Pee D . Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data. Ann Hum Genet. 2004; 68(Pt 5):498-508. DOI: 10.1046/j.1529-8817.2003.00111.x. View

20.

Turesson I, Linet M, Bjorkholm M, Kristinsson S, Goldin L, Caporaso N . Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007; 121(10):2260-6. DOI: 10.1002/ijc.22912. View